Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03672266 · ClinicalTrials.gov registry record
Studies of Brain and Body Interaction
A clinical trial of Alzheimer Disease and ADHD, sponsored by Rutgers University.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT03672266 is a study of Alzheimer Disease and ADHD that is actively recruiting participants, run by Rutgers University. The registered enrollment target is 100 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03672266, a study of Alzheimer Disease and ADHD, is actively recruiting participants, sponsored by Rutgers University.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to characterize biophysiolgoical signals as a comprehensive profile of the nervous systems in order to understand interactions between the brain and body, while an individual performs naturalistic behaviors (ex. walking, pointing) and while breathing at a slow controlled pace. The investigators aim to study these interactions among a variety of populations, from healthy individuals to those with disorders such as Autism Spectrum Disorder(s), including those who may also have an ADHD (Attention-deficit/hyperactivity disorder) diagnosis, Asperger's Syndrome, Alzheimer's Disease, and/or Fragile X syndrome
Conditions Studied
Study Locations (1)
New Jersey
- Rutgers University - Piscataway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2026-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03672266
The ClinicalTrials.gov registry entry for NCT03672266 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The listed sponsor is Rutgers University, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03672266 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT03672266 about?
NCT03672266 is a clinical study titled "Studies of Brain and Body Interaction". The goal of this study is to characterize biophysiolgoical signals as a comprehensive profile of the nervous systems in order to understand interactions between the brain and body, while an individual performs naturalistic behaviors (ex. walking, pointing) and while breathing at a slow controlled pa...
What is the current status of trial NCT03672266?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2018-08-01. Estimated completion is 2026-07-01.
What conditions does trial NCT03672266 study?
This clinical trial studies the following conditions: Alzheimer Disease, ADHD, Dementia With Lewy Bodies, Asperger Syndrome, Dementia Alzheimer Type.
Who is sponsoring clinical trial NCT03672266?
This trial is sponsored by Rutgers University, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03672266 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.